Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.

Therapeutic drug monitoring - 1 Apr 2012

Siccardi Marco, DʼAvolio Antonio, Rodriguez-Novoa Sonia, Cuenca Lorena, Simiele Marco, Baietto Lorena, Calcagno Andrea, Moss Darren, Bonora Stefano, Soriano Vicente, Back David J, Owen Andrew, Di Perri Giovanni

Abstract excerpt

INTRODUCTION: Raltegravir (RAL) is the first in class integrase inhibitor and is licensed for administration at 400 mg twice daily. RAL pharmacokinetics are characterized by high interpatient variability and recently RAL plasma exposure has been correlated with efficacy. RAL is primarily metabolized by glucuronidation via uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) and UGT1A1*28 considered to be the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Interactions
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to HIV Integrase Inhibitors

Share to Oligopeptides

Share to Pyridines

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 22406652
DOI: 10.1097/FTD.0b013e31824aa50a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.PMID 22406652Read ↗

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.Semantic proximity Read ↗

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.Semantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.Semantic proximity Read ↗

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.